Ballicules.com

Methylphenidate ER chewable

QUILLICHEW ER

What it isExtended-release methylphenidate blocking dopamine and norepinephrine reuptake (QUILLICHEW ER, 2015); ADHD.

Why this oneThe chewable uses 30% IR / 70% ER, with 8-12 h (Carlat Table 1) of action.

What limits itAppetite loss, insomnia, cardiovascular stimulation, and abuse risk remain those of methylphenidate.

FDA-approved for

FDA label

BOXED WARNING High potential for abuse, misuse, and addiction; misuse/abuse of CNS stimulants can result in overdose and death. Assess abuse risk before prescribing and monitor during treatment.
FDA dosingPopulationStartTargetMax
Attention deficit hyperactivity disorder (ADHD)patients ≥6 years20 mg QD in the morningtitrate weekly by 10, 15, or 20 mg/day60 mg/day

Titration Titrate weekly in increments of 10, 15, or 20 mg/day.

Renal Undefined

Hepatic Undefined

Not recommended in pediatric patients younger than 6 years.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Limited data insufficient to inform drug-associated risk; no teratogenicity in animal studies at multiples of human dose.

Lactation Methylphenidate present in human milk (infant dose 0.16–0.7% of maternal weight-adjusted dose); monitor infant.

⚠ BOXED WARNING

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Methylphenidate ER chewable ballicule

Methylphenidate ER chewable ballicule: receptor binding, kinetics and half-life diagram

Open Methylphenidate ER chewable in the interactive console ↗

Memory aids: mascots and interaction avatars

Methylphenidate ER chewable METHYLPHENIDATE mascot mnemonic cartoon
“Quill achoo!”
Scantron → methylphenidate product
It’s chewable
Methylphenidate ER chewable no kinetic interactions avatar
no kinetic interactions

Open Methylphenidate ER chewable in the interactive console ↗